Alunno Alessia, Carubbi Francesco, Giacomelli Roberto, Gerli Roberto
1Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.
2Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
BMC Rheumatol. 2017 Nov 28;1:3. doi: 10.1186/s41927-017-0001-8. eCollection 2017.
In recent years, the landscape of pro- and anti-inflammatory cytokines has rapidly expanded with the identification of new members proven to be involved at different extent in the pathogenesis of chronic immune mediated inflammatory diseases including rheumatoid arthritis (RA). The advance of our understanding of mediators involved in the pathogenesis of RA and in consequence, the development of novel targeted therapies is necessary to provide patients not responding to currently available strategies with novel compounds. The aim of this review article is to provide an overview on recently identified cytokines, emphasizing their pathogenic role and therapeutic potential in RA. A systematic literature review was performed to retrieve articles related to every cytokine discussed in the review. In some cases, evidence from animal models and RA patients is already consistent to move forward into drug development. In others, conflicting observation and the paucity of data require further investigations.Forty years after the discovery of IL-1, the landscape of cytokines is continuously expanding with increasing possibilities to develop novel therapeutic strategies in RA.
近年来,随着新成员的发现,促炎和抗炎细胞因子的格局迅速扩展,这些新成员已被证明在包括类风湿关节炎(RA)在内的慢性免疫介导炎症性疾病的发病机制中不同程度地发挥作用。深入了解参与RA发病机制的介质,并在此基础上开发新的靶向治疗方法,对于为目前现有治疗策略无反应的患者提供新的化合物至关重要。这篇综述文章的目的是概述最近发现的细胞因子,强调它们在RA中的致病作用和治疗潜力。我们进行了系统的文献综述,以检索与综述中讨论的每种细胞因子相关的文章。在某些情况下,来自动物模型和RA患者的证据已经一致,可以推进药物开发。在其他情况下,相互矛盾的观察结果和数据的匮乏需要进一步研究。在白细胞介素-1发现40年后,细胞因子格局不断扩展,在RA中开发新治疗策略的可能性越来越大。